* Castle Biosciences Inc CSTL.OQ reported a quarterly
adjusted
loss of 9 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of $-1.10. The mean expectation of nine analysts
for the quarter was for a loss of 33 cents per share. Wall
Street expected results to range from -57 cents to -17 cents per
share.
* Revenue rose 73.6% to $72.97 million from a year ago;
analysts
expected $66.20 million.
* Castle Biosciences Inc's reported EPS for the quarter was
a loss
of 9 cents.
* The company reported a quarterly loss of $2.53 million.
* Castle Biosciences Inc shares had risen by 3.1% this
quarter and
gained 5.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 60.9%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "strong buy"
Wall Street's median 12-month price target for Castle
Biosciences Inc is $34.00
This summary was machine generated from LSEG data May 3 at 07:56
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.33 -0.09 Beat
Dec. 31 2023 -0.54 -0.10 Beat
Sep. 30 2023 -0.76 -0.26 Beat
Jun. 30 2023 -0.91 -0.70 Beat